News on immunoassay systems and applications.

The firm's CEO said that its assay is applicable in other indications where immunosuppressive therapies are used, such as rheumatoid arthritis.

The new testing method used by Quest was developed at Johns Hopkins and leverages a big data approach to achieve personalized calculations.

The firm is now in talks with commercialization and distribution partners to make the test widely available in Europe and other markets that recognize the CE mark. 

The PCR-based test, run on Roche's Liat platform, was among several other assays that was cleared by the agency last month. 

A three-year BARDA-supported contract requires that the developers participate in studies needed to support applying for a pre-emergency use authorization from the FDA.